Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose Travoprost
Open-angle GlaucomaOcular HypertensionThe purpose of this study is to compare the safety and IOP-lowering efficacy of various low dose travoprost formulations in patients with open-angle glaucoma or ocular hypertension.
Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension
Ocular HypertensionOpen-angle GlaucomaThe purpose of this study was to describe the safety and IOP-lowering efficacy of Travoprost New Formulations compared to TRAVATAN® and to vehicle in patients with open-angle glaucoma or ocular hypertension.
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension...
Open-Angle GlaucomaOcular HypertensionTo investigate the dose-response relationship of DE-104 ophthalmic solution in lowering intraocular pressure (IOP) in subjects with Primary Open-Angle Glaucoma or Ocular Hypertension
Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health
Open-angle GlaucomaOcular HypertensionThe purpose of the study is to compare two ophthalmic solutions in patients with open-angle glaucoma or ocular hypertension.
Prospective Evaluation of Open-Angle Glaucoma Subjects on One Topical Hypotensive Medication Treated...
Subjects With Primary Open-angle Glaucoma (POAG)The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of two iStent devices in eyes of subjects with primary open-angle glaucoma
Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated...
Subjects With Primary Open-angle Glaucoma (POAG)The purpose of this study is to assess efficacy and safety of two iStents for the reduction of intraocular pressure associated with primary open-angle glaucoma.
Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular...
Open-Angle GlaucomaOcular HypertensionThe purpose of thie study is to compare the safety and IOP-lowering efficacy of AL-37807 Ophthalmic Solution 0.05%, 0.1% and 0.2% dosed QD AM to Xalatan dosed QD PM and Vehicle in patients with open-angle glaucoma or ocular hypertension
Patient Preference Comparison of AZARGA Versus COSOPT
Open-Angle GlaucomaOcular HypertensionThe purpose of this study was to assess patient preference regarding ocular comfort of AZARGA® compared to COSOPT® after one week instillation of each study medication.
Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle...
GlaucomaThe purpose of this study is to assess the safety and efficacy of Travoprost 0.004% and Tafluprost 0.0015% in patients with primary open angle glaucoma or ocular hypertension when both medications are administered in the evening.
Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension...
Open Angle GlaucomaOcular HypertensionA single-blind , 12-week, parallel group clinical study is planned to evaluate the efficacy and safety of SPARC0912 and Reference0912. SPARC0912 is an experimental drug having similar active ingredient but containing a different preservative as that in Reference0912. Patients with open angle glaucoma or ocular hypertension will be enrolled and randomly assigned to receive either product. One drop will be instilled to the study eye nightly at 8:00 PM.
